TITLE:
An Analysis of the Accounting Costs Associated with 20-Month DR TB Regimens in Maputo City, Mozambique
AUTHORS:
Júlia Malache António, Isaías Benzana, Isabelle Munyangaju, Benedita José, Dulce Osório, Edy Nacarapa, Claudia Mutaquiha, Simeão Nhabinde, Pereira Zindoga
KEYWORDS:
Antitubercular Agents, Multidrug-Resistant, Healthcare Costs, Tuberculosis, Mozambique
JOURNAL NAME:
Journal of Tuberculosis Research,
Vol.12 No.2,
April
29,
2024
ABSTRACT: Introduction: Socioeconomic and demographic conditions in a country can influence tuberculosis incidence and mortality, with nearly 95% of tuberculosis-related deaths occurring in poorer countries. Mozambique is among the 30 countries with the highest TB burden. Objective: The study aimed to estimate the average direct medical cost of treating drug-resistant tuberculosis in 19 health centers in Maputo City, Mozambique. Methods: A retrospective analysis of direct medical costs was conducted on patients aged 18 and older who completed 20-month drug-resistant tuberculosis treatment regimens in Maputo City in 2019. Results: This analysis covered 140 patients who completed a 20-month treatment regimen, with 64.3% (78) being male and 35.7% (62) female. Approximately 50% of the participants were aged between 29 and 47. The average direct medical cost of DRTB treatment was $4789.43, reaching up to $6568.00, with a standard deviation of $753.26, including clinical interventions and treatment. Conclusion: The direct medical costs for a basic treatment package for a patient with drug-resistant TB in Mozambique equal 36 minimum wages. Developing alternative and innovative funding mechanisms and identifying ways to mitigate costs through the use of generic medicines would be beneficial.